Literature DB >> 12794128

Mitochondrial membrane hyperpolarization hijacks activated T lymphocytes toward the apoptotic-prone phenotype: homeostatic mechanisms of HIV protease inhibitors.

Paola Matarrese1, Lucrezia Gambardella, Antonio Cassone, Stefano Vella, Roberto Cauda, Walter Malorni.   

Abstract

A decrease of mitochondrial membrane potential has been hypothesized to be a marker of apoptotic cells, including activated T lymphocytes. It was recently demonstrated that HIV protease inhibitors, independently from any viral infection, can hinder lymphocyte apoptosis by influencing mitochondrial homeostasis. To analyze the mechanisms underlying these effects, a specific study was undertaken in both resting and activated human PBL exposed to either receptor (e.g., anti-Fas)- or nonreceptor (e.g., radiation)-mediated apoptotic stimuli. T cell activation was found to be accompanied by a significant increase in mitochondrial membrane potential, or hyperpolarization, which was undetectable in resting cells. We also detected apoptotic hindering by HIV protease inhibitors only in activated T lymphocytes. This was apparently due to the ability of these drugs to block activation-associated mitochondria hyperpolarization, which, in turn, was paralleled by an impairment of cell cycle progression. Remarkably, protease inhibitors also prevented zidovudine-mediated mitochondrial toxicity. Finally, HIV-infected cells from naive patients behaved identically to activated T cells, displaying hyperpolarized mitochondria, while lymphocytes from patients under highly active antiretroviral therapy (which included HIV protease inhibitors) seemed to react as resting cells. Altogether these results clearly indicate that the hyperpolarization state of mitochondria may represent a prerequisite for the sensitization of lymphocytes to the so-called activation-induced cell death. They also suggest that HIV protease inhibitors, by interfering with induction of the mitochondrial hyperpolarization state, can result in cell survival even independent of any viral infection.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12794128     DOI: 10.4049/jimmunol.170.12.6006

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  21 in total

1.  Inhibition of adenine nucleotide translocator pore function and protection against apoptosis in vivo by an HIV protease inhibitor.

Authors:  Joel G R Weaver; Agathe Tarze; Tia C Moffat; Morgane Lebras; Aurelien Deniaud; Catherine Brenner; Gary D Bren; Mario Y Morin; Barbara N Phenix; Li Dong; Susan X Jiang; Valerie L Sim; Bogdan Zurakowski; Jessica Lallier; Heather Hardin; Peter Wettstein; Rolf P G van Heeswijk; Andre Douen; Romano T Kroemer; Sheng T Hou; Steffany A L Bennett; David H Lynch; Guido Kroemer; Andrew D Badley
Journal:  J Clin Invest       Date:  2005-07       Impact factor: 14.808

Review 2.  HIV protease inhibitors impact on apoptosis.

Authors:  Stacey A Rizza; Andrew D Badley
Journal:  Med Chem       Date:  2008-01       Impact factor: 2.745

Review 3.  Mitochondrial membrane potential probes and the proton gradient: a practical usage guide.

Authors:  Seth W Perry; John P Norman; Justin Barbieri; Edward B Brown; Harris A Gelbard
Journal:  Biotechniques       Date:  2011-02       Impact factor: 1.993

4.  Single-walled carbon nanotubes repress viral-induced defense pathways through oxidative stress.

Authors:  Hao Chen; Sara T Humes; Sarah E Robinson; Julia C Loeb; Indu V Sabaraya; Navid B Saleh; Ram B Khattri; Matthew E Merritt; Christopher J Martyniuk; John A Lednicky; Tara Sabo-Attwood
Journal:  Nanotoxicology       Date:  2019-09-27       Impact factor: 5.913

Review 5.  Adjunctive therapies for HIV-1 associated neurologic disease.

Authors:  S W Perry; J P Norman; H A Gelbard
Journal:  Neurotox Res       Date:  2005-10       Impact factor: 3.911

6.  Cellular Redox Profiling Using High-content Microscopy.

Authors:  Tom Sieprath; Tobias Corne; Joke Robijns; Werner J H Koopman; Winnok H De Vos
Journal:  J Vis Exp       Date:  2017-05-14       Impact factor: 1.355

Review 7.  Mitochondria in traumatic brain injury and mitochondrial-targeted multipotential therapeutic strategies.

Authors:  Gang Cheng; Rong-hua Kong; Lei-ming Zhang; Jian-ning Zhang
Journal:  Br J Pharmacol       Date:  2012-10       Impact factor: 8.739

8.  HIV protease inhibitors provide neuroprotection through inhibition of mitochondrial apoptosis in mice.

Authors:  Toshio Hisatomi; Toru Nakazawa; Kousuke Noda; Lama Almulki; Shinsuke Miyahara; Shintaro Nakao; Yasuhiro Ito; Haicheng She; Riichiro Kohno; Norman Michaud; Tatsuro Ishibashi; Ali Hafezi-Moghadam; Andrew D Badley; Guido Kroemer; Joan W Miller
Journal:  J Clin Invest       Date:  2008-06       Impact factor: 14.808

9.  Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) induced mitochondrial pathway to apoptosis and caspase activation is potentiated by phospholipid scramblase-3.

Authors:  Kenneth Ndebele; Philimon Gona; Tai-Guang Jin; Nordine Benhaga; Anas Chalah; Mauro Degli-Esposti; Roya Khosravi-Far
Journal:  Apoptosis       Date:  2008-07       Impact factor: 4.677

Review 10.  Mitochondrial hyperpolarization: a checkpoint of T-cell life, death and autoimmunity.

Authors:  Andras Perl; Peter Gergely; Gyorgy Nagy; Agnes Koncz; Katalin Banki
Journal:  Trends Immunol       Date:  2004-07       Impact factor: 16.687

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.